Bezalip Retard tablets 400 mg, Bezalip Mono 400 mg tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

Medicine status: No longer supplied Details

Medicine strength:: 400 mg
Still supplied:: Bezafibrate Crescent 400 mg prolonged-release tablets

Bezalip Mono

Bezalip Mono 400 mg

Bezalip Mono 400 mg tablets

Lipozate 400 mg prolonged-release tablets

Bezalip Mono, Calberzol XL 400 mg prolonged-release tablets (SmPC only)

The same active substance, strength and form in the NHS Dictionary of Medicines and Devices (dm+d). Ask your pharmacist or doctor before changing to another make.
Contains active substance:: Bezafibrate
ATC code:: C10AB02 bezafibrate
Similar medicines:: Bezafibrate

Lipantil Micro

Lopid

Summary of Product Characteristics (SmPC) - Bezalip Retard tablets 400 mg, Bezalip Mono 400 mg tablets

Sources: Original (products.mhra.gov.uk)

Facts about Bezalip Retard tablets 400 mg, Bezalip Mono 400 mg tablets

Active substance	Bezafibrate
Strength	400 mg
Pharmaceutical form	Modified-release tablet
How is it taken	Oral
Is it available?	No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)	C Cardiovascular system drugs C10 Lipid modifying agents C10A Lipid modifying agents, plain C10AB Fibrates, lipid modifying drugs, plain C10AB02 bezafibrate
Codes	BNF 02120000

Sources: the NHS Dictionary of Medicines and Devices (dm+d), release 11.0.0 of 2 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.